by Stacey Hawkins | Nov 5, 2019 | Genetic Disease
A Breath of fresh air for cystic fibrosis patients It’s not often that a radical treatment for a chronic, often fatal, disease comes around. The WEEKLY takes notice when one does. Vertex Pharmaceuticals’ (Boston, MA) innovative new drug, Trikafta, promises better... 
by Stacey Hawkins | Sep 7, 2017 | Immunotherapies
THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US market. Classified as a “cell-based gene therapy,” Novartis’... 
by Stacey Hawkins | May 25, 2017 | Immunotherapies
The Drug Kingpins Monoclonal antibodies (mAbs) are the undisputed drug kingpins. In 2013, the mAb market raked in $75 billion in combined sales, covering a whole range of indications from cancer and infectious disease, to autoimmune disorders, and even high... 
by Stacey Hawkins | Mar 2, 2017 | Stem Cells/Regenerative Medicine
Inducing Stem Cells To Heal Headlines touting stem cells often claim the therapies heal everything from hair loss to hearing loss. While many of these treatments are not FDA approved, there are some promising innovations winding through preclinical and clinical... 
by Stacey Hawkins | Jan 19, 2017 | Immunotherapies
Understanding CAR-T Safety Chimeric antigen receptor therapy (CAR-T) is our top technology pick of 2016, blazing trails in drug development with its innovative approach of using engineered immune cells to fight cancer. Despite its success in clinical trials, safety...
